Nerandomilast is posed to be Boehringer Ingelheim’s successor to its blockbuster Ofev (nintedanib)in IPF and PPF.

Regeneron has reported positive outcomes from the Phase III trial of Eylea HD in treating individuals with macular oedema ...

Malwarebytes’ free edition is good at removing pesky malware, but bugs, tie-ins to paid services, crashes, and lack of an ...

Over twelve thousand GFI KerioControl firewall instances are exposed to a critical remote code execution vulnerability ...

Virtual Workspace Solution Market to USD 64 bn by 2034, will be driven by a 13.5% CAGR, highlighting opportunities for ...